Consultant in neuroscience drug development, child neurology and lifestyle medicine
Neurology
Dr. Amy S. Chappell, MD
|
|
Give Review
Doctor Amy S. Chappell, MD practices Neurology. She graduated from Indiana University School of Medicine. Indiana University School of Medicine is ranked 45/47 in Research/PrimaryCare. Chappell has written publications. She has 44 publications published with PubMed. The lastest publication is: 'AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans.' Chappell is registered with Medicare.
Publications
- Results from Clinical Trials of a Selective Ionotropic Glutamate Receptor 5 (iGluR5) Antagonist, LY5454694 Tosylate, in 2 Chronic Pain Conditions.
- Safety, tolerability, pharmacokinetics, and effects on human experimental pain of the selective ionotropic glutamate receptor 5 (iGluR5) antagonist LY545694 in healthy...
- Tailoring chronic pain treatments for the elderly: are we prepared for the challenge?
- Efficacy of Duloxetine in Patients with Chronic Pain Conditions.
- Estimation of minimum clinically important difference for pain in fibromyalgia.
- A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee.
- Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia.
- Efficacy and safety of duloxetine in patients with chronic low back pain.
- Maintenance of effect of duloxetine in patients with chronic low back pain: a 41-week uncontrolled, dose-blinded study.
- Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder.
- Duloxetine for the treatment of recurrent major depressive disorder in elderly patients: treatment outcomes in patients with comorbid arthritis.
- A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia.
- Brain functional changes and duloxetine treatment response in fibromyalgia: a pilot study.
- Efficacy of duloxetine in patients with fibromyalgia: pooled analysis of 4 placebo-controlled clinical trials.
- An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain.
- Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review.
- Duloxetine for the management of diabetic peripheral neuropathic pain: evaluation of functional outcomes.
- Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain.
- A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia.
- Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials.
- Effect of duloxetine in patients with fibromyalgia: tiredness subgroups.
- A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis.
- Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial.
- Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain.
- Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind...
- The relationship between antidepressant and analgesic responses: findings from six placebo-controlled trials assessing the efficacy of duloxetine in patients with majo...
- A crossover, add-on trial of talampanel in patients with refractory partial seizures.
- The clinical importance of changes in the 0 to 10 numeric rating scale for worst, least, and average pain intensity: analyses of data from clinical trials of duloxetin...
- A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain.
- Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations.
- AMPA potentiator treatment of cognitive deficits in Alzheimer disease.
- AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans.
- Effects of the 2-amino-3-hydroxy-5-methyl-4-isoxazole-proprionic acid/kainate antagonist LY293558 on spontaneous and evoked postoperative pain.
- Talampanel, a novel noncompetitive AMPA antagonist, is neuroprotective after traumatic brain injury in rats.
- Zatosetron, a 5-HT3 receptor antagonist in a multicenter trial for acute migraine.
- LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine.
- Pearls and pitfalls of clinical trial investigation: should I get involved in the drug development process?
- Visual loss and performance in blind athletes.
- Effects of alcohol deprivation on alcohol consumption using a sipper-tube procedure.
- Multiple-dose plasma pharmacokinetic and safety study of LY450108 and LY451395 (AMPA receptor potentiators) and their concentration in cerebrospinal fluid in healthy h...
- Measuring ethanol-seeking behavior: the effect of using repeated extinction trials.
- Muscimol injected into the medial prefrontal cortex of the rat alters ethanol self-administration.
- Injected muscimol in pedunculopontine tegmental nucleus alters ethanol self-administration.
Schools
Indiana University School of Medicine
Indiana University School Of Med
Johns Hopkins Hospital
Doctors Specialties
- Pediatric Neurology
- Neurology
Accepted Insurances
Education
-
Indiana University School of Medicine -
Johns Hopkins University
Drug Facts
| NPI NUMBER | 1508007824 | |
| NPPES Provider LastName | CHAPPELL | |
| NPPES Provider FirstName | AMY | |
| NPPES Provider ZIPCode | 142630001 | |
| NPPES Provider State | NY | |
| Specialty Description | Physician Assistant | |
| Total Claim Count | 52.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 16.0 | |
| Percent Opioid Claims | 30.77 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1508007824 |
| Last Name Of The Provider | CHAPPELL |
| First Name Of The Provider | AMY |
| View All |
Similar Doctors
|
|
Dr. Maxim V. Mokin, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Peyman Shirani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Petronio Ilagan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael A. Meyer, MD |
|
|
Dr. Leonardo G. Fugoso Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tobias B. Kulik, MD |
|
|
Dr. Christopher J. Deline, MD
This Doctor is OpenDoctor Recommended.
|